Scarica l'app Stockscreener
90.13
1.66%
1.47
Dopo l'orario di chiusura:
90.20
0.07
+0.08%
Biontech Se Adr Borsa (BNTX) Ultime notizie
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - Zacks Investment Research
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
BioNTech SE stock gains as Berenberg lifts price target after recent pullback - AD HOC NEWS
BioNTech stock heads into the open after a 2.9 percent Nasdaq drop - AD HOC NEWS
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? - TradingView
BioNTech's Downsizing Signal: Factory Divestitures and a Trimmed Forecast Frame the Pipeline Debate - aktiencheck.de
BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Why Pfizer Stock Was so Healthy in August - The Motley Fool
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Why is BioNTech stock sliding today? - investing.com
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
BioNTech's Balancing Act: A COVID Lifeline Arrives Just as Oncology Investors Need a Reason to Stay - aktiencheck.de
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - easternprogress.com
BioNTech's High-Stakes Seoul Debut: A Cash-Rich Pivot Meets Its First Real Test () - aktiencheck.de
BioNTech's September Test: Can Oncology Data Outweigh a Shrinking COVID Franchise? () - aktiencheck.de
BioNTech SEADR (BNTX) Fundamental & Financial Data - Stocktwits
BioNTech (NASDAQ: BNTX) investor moves to sell shares; filing shows how big - Stock Titan
BioNTech's Seoul Moment: Why One Halted Trial Hasn't Derailed the Oncology Narrative () - aktiencheck.de
BioNTech's September Crossroads: Seoul Data Readouts and Factory Decisions Will Test the Post-Trial Narrative - aktiencheck.de
BioNTech's Two-Front Battle: Legal Overhang in Europe Meets a Pivotal September for Oncology Data - aktiencheck.de
BNTX stock reacts to halted cancer trial and lower 2026 guidance - AD HOC NEWS
Zacks Investment ResearchGlobes - Globes - Israel Business News
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down - Eastern Progress
BioNTech's Leadership Exodus Looms as Vaccine Franchise Holds While Oncology Ambitions Take a Hit - aktiencheck.de
BioNTech's Split-Screen Week: A Trial Halted, a Vaccine Approved, and a Pipeline Under the Microscope - aktiencheck.de
BioNTech SEADR Peer Comparison – Compare with Others - Value Research
Why is BioNTech stock down 7.8% today? - tradersunion.com
BioNTech SEADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
BioNTech SEADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BioNTech stock tumbles 10% on cancer trial termination - Investing.com
BioNTech Shares Drop 6.6% After Board Terminates Colorectal Cancer Vaccine Study - TechStock²
BioNTech Stock Falls. It Can’t Match Moderna’s mRNA Cancer Vaccine Win. - Barron's
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine - Barchart.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
FDA approves Pfizer-BioNTech COVID vaccine targeting XFG variant - investing.com
global market • stocks • Vienna Stock Exchange - wienerborse.at
Should You Buy Moderna Stock Following Its Cancer Breakthrough? - TradingView
BioNTech (BNTX) Financial Update: EPS Comes in Below Forecast in the Available Record; Price Reaction: Shares Move 4.40% Lower on the DayDividend Cut Risk - dars.gov.et
BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing - Barchart.com
BioNTech (BNTX) Financial Update: EPS Comes in Below Forecast in the Available Record; Price Reaction: Shares Move 4.40% Lower on the DayLow Estimate Range - dars.gov.et
Market Wrap: Stocks Fall as Industrials and Utilities Decline - Morningstar
BioNTech’s New HIV RNA Vaccine Trial: What Investors Should Watch Now - TipRanks
BioNTech jumps $5.1 billion in premarket; analyst target now just 8% higher - TechStock²
Is Cancer the Next Breakthrough for Moderna After COVID-19? - TradingView
Moderna ascends more than 175% from cancer vaccine breakthrough - Mugglehead Investment Magazine
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 - Barchart.com
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):